hotspot -WSS

hotspot

author：hotspot 2025-10-02 19:15:25 - browse：113

A sign of Gilead Sciences sits in front of its headquarter and next to a pedestrian crossing sign — health coverage from STAT — Justin Sullivan/Getty Images

The assault on the development of new lifesaving therapies continues apace. Recently, the First Appellate Division of California Appeals held that companies not only have to defend products they have developed and marketed, but also those they have not.

In 2001, Gilead secured FDA approval of tenofovir disoproxil fumarate (TDF), one of first medicines to treat HIV — a product still on the market, despite the potential side effect of causing skeletal and kidney damage. In the years that followed, the company invested in research leading to additional TDF-based regimens critical to the fight against HIV. It had also done preliminary work on a similar but different drug — tenofovir alafenamide fumarate (TAF) — for which it had early, although not definitive, evidence for safety and efficacy.

Ultimately, this medicine was shown to have a better side effect profile than TDF. Starting in 2018, plaintiffs began suing Gilead for negligently failing to develop TAF earlier, on the theory that it wanted to protect the profits from TDF. Now, the California court has agreed to let the suit proceed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Mark Cuban is blaming the wrong people for high drug costs

WSS

Biden administration begins canceling student loan debt for 804,000 borrowers

Mark Cuban is blaming the wrong people for high drug costs

Biogen’s boardroom scandal saddles CEO with first crisis

Scientists boost immune system in aging mice by making it youthful

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

Patient advocates debate FDA's accelerated approval process

focus

hotspot

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Decaf coffee targeted by food safety group under obscure FDA rule

Peter Hotez and the public health issue of online harassment

Washington mulls new rules to avert another Change Healthcare

Peter Hotez and the public health issue of online harassment

There's no autism epidemic. It's an autism diagnosis epidemic

Continuity nursing helped my family in our darkest PICU moments

YouTube cracks down on misinformation on cancer treatment

Tori Bowie and the unacceptable rates of Black maternal death

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

hotspot

What to know about the judge who will handle the Trump case

Aspartame and sugar

Hospitals are dialing back on venture capital investing

Scientists boost immune system in aging mice by making it youthful

There's no autism epidemic. It's an autism diagnosis epidemic

Eliminate the waiting period for sterilization covered by Medicaid

leisure time

knowledge

entertainment

entertainment